| scholarly article | Q13442814 |
| P50 | author | Gianantonio Rosti | Q66370842 |
| Richard M Stone | Q86566342 | ||
| Andreas Hochhaus | Q37829812 | ||
| Richard A. Larson | Q41899936 | ||
| Elisabetta Abruzzese | Q42610677 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| P2093 | author name string | Jane F Apperley | |
| Hyeoung-Joon Kim | |||
| Gail J Roboz | |||
| H Jean Khoury | |||
| Jeffrey H Lipton | |||
| Dong-Wook Kim | |||
| Lydia Roy | |||
| Timothy P Hughes | |||
| Philipp Erben | |||
| Christian Sillaber | |||
| Eduardo O Bullorsky | |||
| Dominik Heim | |||
| Carmino A de Souza | |||
| Jan Van Tornout | |||
| P2860 | cites work | Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck | Q28138004 |
| The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants | Q28243392 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tra | Q31034167 | ||
| Gene expression changes associated with progression and response in chronic myeloid leukemia | Q34479561 | ||
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Q34567629 | ||
| Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study | Q34627586 | ||
| Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. | Q35119075 | ||
| Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. | Q36545341 | ||
| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy | Q38361603 | ||
| In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants | Q40414595 | ||
| A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. | Q40549569 | ||
| Chronic myelogenous leukemia: a concise update | Q40828907 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. | Q44267685 | ||
| Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up | Q45301057 | ||
| Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience | Q46437707 | ||
| Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth | Q48192207 | ||
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis | Q53338643 | ||
| Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure | Q57731587 | ||
| Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy | Q58023949 | ||
| Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase | Q58023953 | ||
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. | Q64911638 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| imatinib | Q177094 | ||
| dasatinib | Q419940 | ||
| chronic myeloid leukemia | Q729735 | ||
| dasatinib monohydrate | Q27139135 | ||
| P304 | page(s) | 3472-3479 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial | |
| P478 | volume | 27 |
| Q37048378 | A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient |
| Q49161617 | A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria |
| Q53283587 | A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia |
| Q38757051 | Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase |
| Q38037648 | Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis |
| Q34270677 | An Update On Dual Src/Abl Inhibitors |
| Q38392673 | Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients |
| Q54167458 | Chronic myelogenous leukemia |
| Q34617628 | Chronic myelogenous leukemia: treatment and monitoring |
| Q95614708 | Chronic myeloid leukaemia |
| Q37773845 | Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? |
| Q38054632 | Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management |
| Q38204330 | Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management |
| Q40957470 | Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring |
| Q26748769 | Chronic myeloid leukemia: reminiscences and dreams |
| Q58023770 | Chronische myeloische Leukämie |
| Q33744855 | Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro |
| Q36462473 | Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| Q33394424 | Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation |
| Q38044753 | Dasatinib for the treatment of Philadelphia chromosome-positive leukemias |
| Q39739850 | Dasatinib for the treatment of chronic myeloid leukemia |
| Q36014173 | Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma |
| Q37350583 | Dasatinib-induced pleural effusion: Chylothorax, an option to consider. |
| Q33397085 | Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. |
| Q37966917 | Development of an Effective Therapy for Chronic Myelogenous Leukemia |
| Q38598820 | Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. |
| Q40539487 | Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia |
| Q26749324 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia |
| Q37026032 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. |
| Q37966915 | Evolution of Therapies for Chronic Myelogenous Leukemia |
| Q59640163 | First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia |
| Q35802202 | How I treat childhood CML |
| Q43117904 | Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case |
| Q39457369 | Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. |
| Q37797981 | Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications |
| Q54347294 | Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors? |
| Q37461942 | Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors |
| Q38767908 | Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase |
| Q38452040 | Management of advanced-phase chronic myeloid leukemia |
| Q37988569 | Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Q34761663 | Monitoring response and resistance to treatment in chronic myeloid leukemia |
| Q37139374 | Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients |
| Q34522789 | NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia |
| Q36125906 | National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011. |
| Q37969405 | Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells |
| Q41524889 | Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case |
| Q35596200 | Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure |
| Q54310937 | Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. |
| Q48503168 | Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors |
| Q35510549 | Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase |
| Q89254762 | Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase |
| Q37781050 | Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development |
| Q38139571 | Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia |
| Q33849146 | Practical management of patients with chronic myeloid leukemia |
| Q38095956 | Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring |
| Q27028181 | Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options |
| Q34293414 | Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations |
| Q38789049 | Second line small molecule therapy options for treating chronic myeloid leukemia |
| Q37952910 | Selection of Therapy: Rational Decisions Based on Molecular Events |
| Q42712043 | Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS |
| Q33399101 | Spotlight on Dasatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia† |
| Q41649368 | Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. |
| Q38079249 | Surrogate end points for long-term outcomes in chronic myeloid leukemia |
| Q24596026 | Systematic review of dasatinib in chronic myeloid leukemia |
| Q54398375 | Tailored management of chronic myeloid leukemia |
| Q37965564 | Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons |
| Q37810070 | Targeting the BCR–ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer |
| Q38128723 | The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients |
| Q36800451 | The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. |
| Q35087994 | The role of dasatinib in the management of chronic myeloid leukemia |
| Q33655352 | Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib |
| Q42657232 | Tools to optimize the functionality of a leukemia clinical trial team |
| Q37827875 | Treatment of chronic myeloid leukemia when imatinib fails |
| Q37994805 | Treatment options for chronic myeloid leukemia |
| Q33391185 | Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib |
| Q33926114 | Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 |
| Q52567954 | Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making |
| Q37647076 | Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase |
| Q38004075 | Tyrosine kinase inhibitors in acute and chronic leukemias |
| Q37738539 | Tyrosine kinase inhibitors: the first decade |
| Q38478174 | Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm |
Search more.